AstraZeneca Results Presentation Deck
BioPharmaceuticals: new launch medicines
Portfolio of new medicines across uses and markets
Leading new biologic in five
of top-seven countries ¹
US, total patient share
Europe $136m (+39%);
Japan $54m (+14%)
100%
US $357m (+31%)
80%
60%
40%
Severe asthma
20%
Fasenra
0%
T
Q4 2017
Q2 2018
Q4 2018
Q2 2019
Q4 2019
Q2 2020
pe24 2020
52%
48%
Q2 2021
Total revenue at actual exchange rates. 1. Market shares are new
patient share in severe, uncontrolled asthma; US: specialty
pharmacies and 'buy and bill' market, IQVIA market research.
17
Breztri
COPD²
US $43m
Achieved >20% share of
new patients³
EM $27m
Continued launch in China;
NRDL inclusion in place
Japan $11m
Achieved >35%
share of new
patients³
ストリエアロスフィア
ピレーズトリ
エアロスフィア
56双入
FASUDAAN
GHASKA
TS
2. Chronic obstructive pulmonary disease 3. New patient share
in triple COPD market, IQVIA market research.
$m
60
50
40
30
20
10
0
Lokelma
Hyperkalaemia
Global $72m; US $49m
US market leadership4, new
and total prescriptions
Global launch continued
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
T₁
Q2 2021
US Europe EROW EM
Total revenue at actual exchange rates. 4. Market leadership in
both total and new-to-medicine patients, IQVIA market research.
$m
60
50
40
30
20
10
0
EM $92m
Recording sales in
China since Q1 2021
US
roxadustat
Anaemia in CKD
Disappointing advisory
committee 15 July 2021;
regulatory decision H2'21
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
EM
Total revenue at actual exchange rates.
Q2 2021
3View entire presentation